12th October 2017 -

Foundation for Neglected Disease Research is happy to announce that its partner, TB Alliance has initiated the Phase 1 clinical trial of TBA-7371, a novel DprE1 inhibitor, for the treatment of tuberculosis. With no pre-existing resistance or cross-resistance with other TB drugs, TBA-7371 could have significant potential in the treatment of TB.

February 2018 –

FNDR won the Economic Times Power of Ideas 2017 Award in March 2018. This award is made by Economic Times and Facebook in partnership with Department of Science & Technology (DST), Government of India and the Centre for Innovation Incubation and Entrepreneurship (CIIE), IIM Ahmedabad. This is India’s largest entrepreneurship development program, given to start ups with promising ideas and a spirit of innovation. FNDR won the award for its diagnostics program in Tuberculosis.